Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Conor Killmurray
Advertisement
Articles by Conor Killmurray
BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.
A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success
2
OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows
3
High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial
4
Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups
5